-+ 0.00%
-+ 0.00%
-+ 0.00%

Bernstein Initiates Coverage On BridgeBio Pharma with Outperform Rating, Announces Price Target of $94

Benzinga·12/11/2025 10:54:55
Listen to the news
Bernstein analyst William Pickering initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and announces Price Target of $94.